Semifluorinated Alkane Drug Delivery for Ocular and Respiratory Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating corneal scarring, refractive errors, cataract complications, glaucoma, and respiratory infections face challenges such as corneal graft rejection, post-operative pain, limited effectiveness of laser surgeries, opacification of the lens capsule, and inadequate drug delivery to the cornea, along with the lack of a reliable method for intraocular pressure measurement and treatment of inflammatory diseases.
Innovation Solution
A method involving cross-linked corneal transplantation, biocompatible drug delivery using semifluorinated alkane and nanoparticles or microparticles for respiratory tract inflammatory diseases, and a corneal lenslet implantation to correct refractive errors, combined with a drug delivery system capable of effectively targeting the cornea and managing inflammatory responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If corneal transplantation is performed to treat corneal scarring, then visual function is restored, but corneal graft rejection occurs
Solution Approach 1:
The patent applies cross-linking treatment to the donor cornea before transplantation to strengthen its structural integrity and reduce immunogenicity. This preliminary modification of the graft tissue helps prevent rejection by altering the corneal properties prior to implantation, thereby improving long-term graft survival while maintaining visual function restoration
2Manufacturing precision
If laser surgery is used to correct refractive errors, then visual acuity is improved, but post-operative pain and limited effectiveness occur
Solution Approach 1:
The patent introduces a drug delivery system using semifluorinated alkane and nanoparticles as intermediaries to administer medications that reduce inflammation and pain after laser surgery. This intermediary delivery mechanism provides controlled release of therapeutic agents to the ocular tissue, managing post-operative discomfort while preserving the refractive correction achieved by laser surgery
3Productivity
If conventional drug delivery methods are used for ocular conditions, then treatment is administered, but inadequate drug delivery to the cornea occurs
Solution Approach 1:
The patent fundamentally changes the physical and chemical parameters of the drug delivery system by using semifluorinated alkane with unique properties (low surface tension, high permeability) and nanoparticle carriers. These parameter changes enable the drug formulation to overcome the corneal barrier more effectively, achieving superior drug penetration and sustained release directly at the target site, thereby improving both delivery efficiency and treatment reliability
4Reliability
If lens capsule opacification occurs after cataract surgery, then vision is restored initially, but visual quality deteriorates over time
Solution Approach 1:
The patent implements continuous anti-proliferative drug delivery through the nanoparticle system to prevent fibroblast migration and capsule opacification over time. This continuous therapeutic action maintains the clarity of the lens capsule throughout the post-operative period, preserving visual quality long-term while maintaining the initial visual restoration achieved by cataract surgery
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method reduces the likelihood of corneal graft rejection, improves refractive error correction, enhances drug delivery to the eye, and effectively treats respiratory tract inflammatory diseases, while providing a stable and centered lens implant and efficient treatment for corneal and ocular conditions.
Implementation Method 1
the semifluorinated alkane evaporating quickly upon administration to the patient so as to leave the biocompatible drug at a desired treatment location
Implementation Method 2
the one or more cell pathway inhibitors blocking an inflammatory response of inflamed tissue without inhibiting an immune response of the patient
Data Source
AI summary
A method of treating, reducing, or alleviating a medical condition in a patient is disclosed herein. The method includes administering to a patient in need thereof a biocompatible drug comprising one or more antiviral medications together with one or more cell pathway inhibitors dissolved in a non-toxic semifluorinated alkane, the patient having one or more respiratory tract inflammatory diseases, the one or more cell pathway inhibitors blocking an inflammatory response of inflamed tissue without inhibiting an immune response of the patient, and the semifluorinated alkane evaporating quickly upon administration to the patient so as to leave the biocompatible drug at a desired treatment location. The administration of the biocompatible drug to the patient treats the one or more respiratory tract inflammatory diseases, reduces the symptoms associated with the one or more respiratory tract inflammatory diseases, and/or alleviates one or more respiratory tract inflammatory diseases.